if tomorrow there is talking about a Chinese partner then we have a new playing field....
Aurobindo Pharma has received US Food and Drug Administration (USFDA) approval to manufacture and market Voriconazole tablets (50 mg and 200 mg) that are used to treat fungal infections.
Announcing this on Wednesday, the company said it expected be launch the product by March. The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product VFEND tablets of PF Prism C.V
- - -
Development of an Inhaled Controlled Release Voriconazole Dry Powder Formulation for the Treatment of Respiratory Fungal Infection
- - - - -
the Technosphere platform has potential applicability for local lung delivery as well as other routes of administration. Technosphere technology has the potential to provide impressive drug delivery solutions across a wide variety of therapeutic areas encompassing a number of diverse products and disease states. -
from the same report,
Novo Nordisk, the biggest insulin maker in China, got almost 10% of its $13.5 billion in 2014 sales from China. And Sanofi said almost 20% of its diabetes sales came from emerging markets in 2014, a large chunk of that coming from China.
Novo Nordisk expects Chinese sales growth to be flat to slightly positive for 2016 after coming in around 5% in 2015, CEO Lars Rebien Sørensen said in October.
...Some companies are already doing that. Sanofi agreed in July to set up a joint venture with Zhejiang Hisun Pharmaceutical Co. Ltd to develop insulin and other diabetes-related treatments.
How big is the potential market for diabetes drugs in China? As big as the entire populations of Australia, Canada and Argentina — combined. And it’s growing.
That has drug manufacturers turning more attention to the world’s most populous country in hope of collecting massive new revenues in the coming decades.
About half of China’s diabetics have been diagnosed, according to health experts. Only 15% of those diagnosed are receiving comprehensive treatment, said Jakob Riis, head of the China business at Novo Nordisk, the world’s largest insulin maker. Increased urbanization and more sedentary lifestyles are expected to produce more patients.
That, market watchers say, means the battle is on for millions of untreated Chinese diabetics and the millions more expected to follow. “The potential, looking at just the existing number of diabetics, is enormous,” said Riis.
‘The opportunity to take market share is gigantic’
have you been there...perhaps the building is empty..nothing seems what it is..remember....
No only in companies with new groundbreaking technologies....so and let Mann have some new breaking technology....
or perhaps misled Sanofi Mann..by saying easely for that price because we have good inroads...sue them